Search results
Added:
1 year ago
Added:
1 year ago
Updates on Chronic Coronary Syndrome
Added:
1 year ago
Editorial
Added:
9 months ago
Navigate the complex landscape of coronary interventions following transcatheter aortic valve replacement with Dr Samineh Sehatbakhsh, addressing critical access challenges in an era of expanding TAVR indications.This essential presentation, part of the Complex Cases track, examines the growing clinical significance of post-TAVR coronary access as procedures expand to younger, lower-risk patients…
View more
Added:
1 month ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc analysis of the SURPASS-CVOT trial suggests that tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a lower incidence of a broad composite of cardiorenal events compared with the GLP-1 receptor agonist dulaglutide in patients with type 2 diabetes and established cardiovascular disease.¹Tirzepatide is a dual agonist that targets both…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have established cardiorenal benefits in type 2 diabetes, long-term data for their use in patients with type 1 diabetes (T1D) have been scarce. A new large-scale study suggests that initiating GLP-1RA therapy is associated with a lower risk of major adverse cardiovascular and kidney outcomes in this population, without compromising safety…
View more
Added:
2 months ago
Added:
1 year ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2…
View more
Added:
2 months ago
Added:
2 months ago